Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
34
FATE Quote, Financials, Valuation and Earnings
Last price:
$0.99
Seasonality move
:
30.36%
Day range:
$0.98 - $1.02
52-week range:
$0.66 - $1.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
16.59x
P/B ratio:
0.49x
Volume:
991.9K
Avg. volume:
1.4M
1-year change:
-38.27%
Market cap:
$115.4M
Revenue:
$13.6M
EPS (TTM):
-$1.32
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
FATE
Fate Therapeutics, Inc.
|
$1.7M | -$0.28 | -35.58% | -38.02% | $4.94 |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
FATE
Fate Therapeutics, Inc.
|
$1.00 | $4.94 | $115.4M | -- | $0.00 | 0% | 16.59x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$4.85 | $0.85 | $611.2M | 8.15x | $0.80 | 0% | 9.42x |
|
NNVC
NanoViricides, Inc.
|
$1.19 | $6.50 | $21.4M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.86 | $2.00 | $706.9K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
FATE
Fate Therapeutics, Inc.
|
25.29% | 2.203 | 54.53% | 7.69x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
FATE
Fate Therapeutics, Inc.
|
-$1.5M | -$34.7M | -41.23% | -53.28% | -1995.12% | -$26.6M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Fate Therapeutics, Inc. vs. Competitors
-
Which has Higher Returns FATE or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -1852.38% compared to Fate Therapeutics, Inc.'s net margin of -255.85%. Fate Therapeutics, Inc.'s return on equity of -53.28% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital FATEFate Therapeutics, Inc.-85.35% -$0.27 $313.3M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About FATE or NBY?
Fate Therapeutics, Inc. has a consensus price target of $4.94, signalling upside risk potential of 394.44%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -82.47%. Given that Fate Therapeutics, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Fate Therapeutics, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FATEFate Therapeutics, Inc.5 6 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is FATE or NBY More Risky?
Fate Therapeutics, Inc. has a beta of 2.338, which suggesting that the stock is 133.825% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock FATE or NBY?
Fate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Fate Therapeutics, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FATE or NBY?
Fate Therapeutics, Inc. quarterly revenues are $1.7M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Fate Therapeutics, Inc.'s net income of -$32.3M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Fate Therapeutics, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fate Therapeutics, Inc. is 16.59x versus 9.42x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FATEFate Therapeutics, Inc.16.59x -- $1.7M -$32.3M NBYNovaBay Pharmaceuticals, Inc.9.42x 8.15x $521K -$1.3M
-
Which has Higher Returns FATE or NNVC?
NanoViricides, Inc. has a net margin of -1852.38% compared to Fate Therapeutics, Inc.'s net margin of --. Fate Therapeutics, Inc.'s return on equity of -53.28% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital FATEFate Therapeutics, Inc.-85.35% -$0.27 $313.3M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About FATE or NNVC?
Fate Therapeutics, Inc. has a consensus price target of $4.94, signalling upside risk potential of 394.44%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 446.22%. Given that NanoViricides, Inc. has higher upside potential than Fate Therapeutics, Inc., analysts believe NanoViricides, Inc. is more attractive than Fate Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FATEFate Therapeutics, Inc.5 6 0 NNVCNanoViricides, Inc.1 0 0 -
Is FATE or NNVC More Risky?
Fate Therapeutics, Inc. has a beta of 2.338, which suggesting that the stock is 133.825% more volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock FATE or NNVC?
Fate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fate Therapeutics, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FATE or NNVC?
Fate Therapeutics, Inc. quarterly revenues are $1.7M, which are larger than NanoViricides, Inc. quarterly revenues of --. Fate Therapeutics, Inc.'s net income of -$32.3M is lower than NanoViricides, Inc.'s net income of -$1.8M. Notably, Fate Therapeutics, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fate Therapeutics, Inc. is 16.59x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FATEFate Therapeutics, Inc.16.59x -- $1.7M -$32.3M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns FATE or OGEN?
Oragenics, Inc. has a net margin of -1852.38% compared to Fate Therapeutics, Inc.'s net margin of --. Fate Therapeutics, Inc.'s return on equity of -53.28% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital FATEFate Therapeutics, Inc.-85.35% -$0.27 $313.3M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About FATE or OGEN?
Fate Therapeutics, Inc. has a consensus price target of $4.94, signalling upside risk potential of 394.44%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 132.83%. Given that Fate Therapeutics, Inc. has higher upside potential than Oragenics, Inc., analysts believe Fate Therapeutics, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FATEFate Therapeutics, Inc.5 6 0 OGENOragenics, Inc.1 0 0 -
Is FATE or OGEN More Risky?
Fate Therapeutics, Inc. has a beta of 2.338, which suggesting that the stock is 133.825% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock FATE or OGEN?
Fate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fate Therapeutics, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FATE or OGEN?
Fate Therapeutics, Inc. quarterly revenues are $1.7M, which are larger than Oragenics, Inc. quarterly revenues of --. Fate Therapeutics, Inc.'s net income of -$32.3M is lower than Oragenics, Inc.'s net income of -$3.1M. Notably, Fate Therapeutics, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fate Therapeutics, Inc. is 16.59x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FATEFate Therapeutics, Inc.16.59x -- $1.7M -$32.3M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns FATE or PTN?
Palatin Technologies has a net margin of -1852.38% compared to Fate Therapeutics, Inc.'s net margin of --. Fate Therapeutics, Inc.'s return on equity of -53.28% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital FATEFate Therapeutics, Inc.-85.35% -$0.27 $313.3M PTNPalatin Technologies-- -- -- -
What do Analysts Say About FATE or PTN?
Fate Therapeutics, Inc. has a consensus price target of $4.94, signalling upside risk potential of 394.44%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Palatin Technologies has higher upside potential than Fate Therapeutics, Inc., analysts believe Palatin Technologies is more attractive than Fate Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FATEFate Therapeutics, Inc.5 6 0 PTNPalatin Technologies0 0 0 -
Is FATE or PTN More Risky?
Fate Therapeutics, Inc. has a beta of 2.338, which suggesting that the stock is 133.825% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock FATE or PTN?
Fate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fate Therapeutics, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FATE or PTN?
Fate Therapeutics, Inc. quarterly revenues are $1.7M, which are larger than Palatin Technologies quarterly revenues of --. Fate Therapeutics, Inc.'s net income of -$32.3M is higher than Palatin Technologies's net income of --. Notably, Fate Therapeutics, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fate Therapeutics, Inc. is 16.59x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FATEFate Therapeutics, Inc.16.59x -- $1.7M -$32.3M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns FATE or TOVX?
Theriva Biologics, Inc. has a net margin of -1852.38% compared to Fate Therapeutics, Inc.'s net margin of --. Fate Therapeutics, Inc.'s return on equity of -53.28% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital FATEFate Therapeutics, Inc.-85.35% -$0.27 $313.3M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About FATE or TOVX?
Fate Therapeutics, Inc. has a consensus price target of $4.94, signalling upside risk potential of 394.44%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3559.17%. Given that Theriva Biologics, Inc. has higher upside potential than Fate Therapeutics, Inc., analysts believe Theriva Biologics, Inc. is more attractive than Fate Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings FATEFate Therapeutics, Inc.5 6 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is FATE or TOVX More Risky?
Fate Therapeutics, Inc. has a beta of 2.338, which suggesting that the stock is 133.825% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock FATE or TOVX?
Fate Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Fate Therapeutics, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios FATE or TOVX?
Fate Therapeutics, Inc. quarterly revenues are $1.7M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Fate Therapeutics, Inc.'s net income of -$32.3M is lower than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Fate Therapeutics, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Fate Therapeutics, Inc. is 16.59x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income FATEFate Therapeutics, Inc.16.59x -- $1.7M -$32.3M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 29
Galecto, Inc. [GLTO] is down 12.13% over the past day.
Sell
20
SMX alert for Dec 29
SMX (Security Matters) Plc [SMX] is down 27.67% over the past day.
Sell
11
CDNAF alert for Dec 29
Canadian Tire Corp. Ltd. [CDNAF] is up 11.94% over the past day.
